Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Breast Cancer
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen…
- Trial name
- NCT01301040
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Jules Bordet Institute
Breast Neoplasm Female, Early-stage Breast Cancer
Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)
This bi-directional, multicentre study aims to assess multiparametric MRI Radiomics-based prediction model for identifying metastasis lymph nodes and prognostic prediction in breast cancer.
- Conditions
- Breast Neoplasm Female, Early-stage Breast Cancer, Radiomics, Axillary Lymph Node
- Trial name
- NCT04003558
- Testing
- No interventions
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Stage Estrogen Receptor (ER) Positive Breast Cancer
Active Surveillance in Older Women With ER+ Breast Cancer
ACTIVE is a prospective, single-arm, phase I/IIa study examining an active surveillance strategy for small, screen-detected, luminal breast cancer.
- Trial name
- ACTIVE (NCT07262138)
- Testing
- Active Surveillance
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Breast Cancer
Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients
Late Cardiac Evaluation of the Three Arm Belgian Trial A phase III randomized trial involving node-positive early breast cancer patients with a long median follow-up (~ 15 years) OBJECTIFS Primary: To compare the incidence of…
- Trial name
- NCT01554943
- Testing
- cardiac MRI
- Where
- Belgium
- Volunteers
- 73 people
- Sponsor
- Jules Bordet Institute
Early Breast Cancer
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
This is a randomized, multicenter, open-label, two-arm, Phase II study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant versus anastrozole (in the window-of-opportunity phase) and giredestrant plus…
- Trial name
- NCT04436744
- Testing
- Giredestrant, Anastrozole, Palbociclib
- Where
- 65 sites in United States, Australia and 9 more
- Volunteers
- 221 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
The goal of this multicenter, two-cohort, exploratory clinical trial is to evaluate patients with early stage hormone receptor-negative breast cancer receiving standard adjuvant chemotherapy after surgery.
- Trial name
- SMA-BC-002 (NCT05978648)
- Testing
- Trilaciclib, Epirubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- wang shusen
HER2-positive Breast Cancer
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
This study was phase IB-II clinical trial that designed to evaluate the efficacy and safety of docetaxel + atezolizumab + Herceptin sc plus pertuzumab(TAHP) plus adjuvant therapy of atezolizumab + trastuzumab + pertuzumab(AHP)…
- Trial name
- NCT03881878
- Testing
- TAHP and AHP, TAHP plus AC and AHP
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Samsung Medical Center
Breast Neoplasms
A Registry Study of Breast Microseed Treatment
For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8…
- Trial name
- NCT02701244
- Testing
- Permanent Breast Seed Implant (PBSI)
- Where
- 3 sites in United States
- Volunteers
- 420 people
- Sponsor
- Concure Oncology-Breast Microseed Inc.
Breast Cancer
Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer
Operable early stage breast cancer patients staged according to NCCN guidelines are subjected to bone marrow aspiration/trephine biopsy at the time of the definitive operation under general anesthesia.
- Trial name
- NCT02921152
- Testing
- bone marrow aspiration /trephine biopsy
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Acibadem University
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Radiation Therapy in Treating Women With Early Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. Giving it after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00909909
- Testing
- External beam boost, whole breast irradiation
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer, Benign Breast Disease
Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System
This observational study evaluates scale-up of a breast cancer early detection program in Rwanda that was initially piloted in a single district.
- Trial name
- NCT04258085
- Testing
- Early diagnosis program combined with electronic medical record
- Where
- Rwanda
- Volunteers
- 17,379 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
Evaluation of the Safety and Efficacy of Single-Port Robot-Assisted Endoscopic Breast-Conserving Surgery and Nipple-sparing Matectomy With Reconstruction in Early-Stage Breast Cancer Patients
This study is testing a new, less invasive way to perform breast cancer surgery using a single-port robotic system (a robot-assisted surgical tool made in China, called the Shurui SR-ENS-600).
- Trial name
- NCT07781163
- Testing
- single-port robot-assisted surgery
- Volunteers
- 30 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer
A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer
This is a prospective, open-label, multicenter, single-arm clinical study designed to compare the efficacy and safety of neoadjuvant treatment with T-DXd in combination with an immune checkpoint inhibitor in patients with primary…
- Trial name
- NCT06733233
- Testing
- T-DXd combined with immune checkpoint inhibitor
- Volunteers
- 23 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Breast Cancer
Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy
The investigators suggested ultrasound-assisted Carbon nanoparticle suspensions (CNSs) mapping had great clinical value in clinical application and might serve as a useful alternative to the dual-tracer-guided SLNB.
- Trial name
- UltraCars (NCT04951245)
- Testing
- UC group: ultrasound-assisted CNSs guided, GC group: CNSs plus ICG dual-tracer-guided
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Guangdong Provincial People's Hospital
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSDD).
- Conditions
- Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
- Trial name
- NCT07596212
- Testing
- Aromatase Inhibitors, Bupropion, GnRH agonist
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Breast Cancer
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA
(Neo)adjuvant treatment approaches and outcomes
- Trial name
- ERA (NCT05939128)
- Where
- 19 sites in Russia
- Volunteers
- 625 people
- Sponsor
- AstraZeneca
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.